Cargando…

Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model

The COVID-19 pandemic has caused unprecedented health, social, and economic crises worldwide. However, to date, there is an only a limited effective treatment for this disease. Human placenta hydrolysate (hPH) has previously been shown to be safe and to improve the health condition in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun-Ha, Kim, Young-il, Jang, Seung-Gyu, Im, Minju, Jeong, Kyeongsoo, Choi, Young Ki, Han, Hae-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Microbiological Society of Korea 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493534/
https://www.ncbi.nlm.nih.gov/pubmed/34613605
http://dx.doi.org/10.1007/s12275-021-1367-2
_version_ 1784579130301349888
author Kim, Eun-Ha
Kim, Young-il
Jang, Seung-Gyu
Im, Minju
Jeong, Kyeongsoo
Choi, Young Ki
Han, Hae-Jung
author_facet Kim, Eun-Ha
Kim, Young-il
Jang, Seung-Gyu
Im, Minju
Jeong, Kyeongsoo
Choi, Young Ki
Han, Hae-Jung
author_sort Kim, Eun-Ha
collection PubMed
description The COVID-19 pandemic has caused unprecedented health, social, and economic crises worldwide. However, to date, there is an only a limited effective treatment for this disease. Human placenta hydrolysate (hPH) has previously been shown to be safe and to improve the health condition in patients with hyperferritinemia and COVID-19. In this study, we aimed to determine the antiviral effects of hPH against SARS-CoV-2 in vitro and in vivo models and compared with Remdesivir, an FDA-approved drug for COVID-19 treatment. To assess whether hPH inhibited SARS-CoV-2 replication, we determined the CC(50), EC(50), and selective index (SI) in Vero cells by infection with a SARS-CoV-2 at an MOI of 0.01. Further, groups of ferrets infected with 10(5.8) TCID(50)/ml of SARS-CoV-2 and treated with hPH at 2, 4, 6 dpi, and compared their clinical manifestation and virus titers in respiratory tracts with PBS control-treated group. The mRNA expression of immune-related cytokines was determined by qRT-PCR. hPH treatment attenuated virus replication in a dose-dependent manner in vitro. In a ferret infection study, treatment with hPH resulted in minimal bodyweight loss and attenuated virus replication in the nasal wash, turbinates, and lungs of infected ferrets. In addition, qRT-PCR results revealed that the hPH treatment remarkably upregulated the gene expression of type I (IFN-α and IFN-β) and II (IFN-γ) IFNs in SARS-CoV-2 infected ferrets. Our data collectively suggest that hPH has antiviral efficacy against SARS-CoV-2 and might be a promising therapeutic agent for the treatment of SARS-CoV-2 infection.
format Online
Article
Text
id pubmed-8493534
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Microbiological Society of Korea
record_format MEDLINE/PubMed
spelling pubmed-84935342021-10-06 Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model Kim, Eun-Ha Kim, Young-il Jang, Seung-Gyu Im, Minju Jeong, Kyeongsoo Choi, Young Ki Han, Hae-Jung J Microbiol Virology The COVID-19 pandemic has caused unprecedented health, social, and economic crises worldwide. However, to date, there is an only a limited effective treatment for this disease. Human placenta hydrolysate (hPH) has previously been shown to be safe and to improve the health condition in patients with hyperferritinemia and COVID-19. In this study, we aimed to determine the antiviral effects of hPH against SARS-CoV-2 in vitro and in vivo models and compared with Remdesivir, an FDA-approved drug for COVID-19 treatment. To assess whether hPH inhibited SARS-CoV-2 replication, we determined the CC(50), EC(50), and selective index (SI) in Vero cells by infection with a SARS-CoV-2 at an MOI of 0.01. Further, groups of ferrets infected with 10(5.8) TCID(50)/ml of SARS-CoV-2 and treated with hPH at 2, 4, 6 dpi, and compared their clinical manifestation and virus titers in respiratory tracts with PBS control-treated group. The mRNA expression of immune-related cytokines was determined by qRT-PCR. hPH treatment attenuated virus replication in a dose-dependent manner in vitro. In a ferret infection study, treatment with hPH resulted in minimal bodyweight loss and attenuated virus replication in the nasal wash, turbinates, and lungs of infected ferrets. In addition, qRT-PCR results revealed that the hPH treatment remarkably upregulated the gene expression of type I (IFN-α and IFN-β) and II (IFN-γ) IFNs in SARS-CoV-2 infected ferrets. Our data collectively suggest that hPH has antiviral efficacy against SARS-CoV-2 and might be a promising therapeutic agent for the treatment of SARS-CoV-2 infection. The Microbiological Society of Korea 2021-10-06 2021 /pmc/articles/PMC8493534/ /pubmed/34613605 http://dx.doi.org/10.1007/s12275-021-1367-2 Text en © The Microbiological Society of Korea 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Virology
Kim, Eun-Ha
Kim, Young-il
Jang, Seung-Gyu
Im, Minju
Jeong, Kyeongsoo
Choi, Young Ki
Han, Hae-Jung
Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model
title Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model
title_full Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model
title_fullStr Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model
title_full_unstemmed Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model
title_short Antiviral effects of human placenta hydrolysate (Laennec(®)) against SARS-CoV-2 in vitro and in the ferret model
title_sort antiviral effects of human placenta hydrolysate (laennec(®)) against sars-cov-2 in vitro and in the ferret model
topic Virology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493534/
https://www.ncbi.nlm.nih.gov/pubmed/34613605
http://dx.doi.org/10.1007/s12275-021-1367-2
work_keys_str_mv AT kimeunha antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel
AT kimyoungil antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel
AT jangseunggyu antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel
AT imminju antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel
AT jeongkyeongsoo antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel
AT choiyoungki antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel
AT hanhaejung antiviraleffectsofhumanplacentahydrolysatelaennecagainstsarscov2invitroandintheferretmodel